A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Recruiting

Phase 2

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisA Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Sponsor:

Novartis Pharmaceuticals

Code:

NCT06470048

Conditions

Diffuse Cutaneous Systemic Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Placebo

Ianalumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information